We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • Drug Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Training
    • Webinar Training Pass
  • Device Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Training
    • Webinar Training Pass
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA Executive Director Rasi Lays Out Vision for Agency

EMA Executive Director Rasi Lays Out Vision for Agency

December 15, 2015

A focus on innovative R&D, a commitment to transparency and patient involvement were among the goals that European Medicines Agency Executive Director Guido Rasi laid out in his vision for the agency during a press briefing last week.

Rasi called for innovative therapies “which have the potential to really improve patients’ lives” and translate into public health benefits. He also touted his agency’s commitment to transparency, noting that the EMA was the first regulator in the world to enable the public to access clinical data used to determine marketing authorizations.

The executive director also stressed the need for more patient involvement “to ensure their views and needs are taken into account at every step of the development process.” Rasi reinforced the agency’s role as a global reference authority, as well as the need to integrate all available evidence when studying the impact of medicines.

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 10Jan

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 12Feb

    Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

  • 17Mar

    FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

  • 19Mar

    SOPs and Policies for the 21st Century: Why Less is More

  • 20Apr

    17th Annual Medical Device Quality Congress

Featured Products

  • Biological-risk-eval-and-mngmnt-for-md-130x160

    Biological Risk Evaluation and Management for Medical Devices

  • Gmp-inspection-preparation-checklist-130x160

    GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • 483sonline-logo-430x250

    483sOnline.com Your Personal Pre-inspection Toolkit

  • Globalmarketimage

    International Devices and Diagnostics Monitor

  • Cryolife_logo

    CryoLife’s Thoracoabdominal Stent Graft Receives CE Mark

  • Patentstablabel

    House Judiciary Committee Advances Patent Abuse Legislation

New!

17th Medical Device Quality Congress

Learn More Here
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578.

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing